March 9, 2025
Update: As Ypsomed executes on its focus on the B2B business, Rothschild is guiding the ongoing sale of the Swiss firm’s B2C insulin pumps business, targeting a signing before the Summer holidays, acc. to sources (NKP | M&A Insights Proprietary)
NKP | M&A Insights Proprietary
Headline from pre-deal coverage in M&A Insights
.png){kind=logo}